| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Coherus BioSciences (NASDAQ:CHRS) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Coherus BioSciences missed estimated earnings by -417.0%, reporting an EPS of $-0.62 versus an estimate of $-0.12.
Revenue was up $46.17 million from the same period last year.
Last quarter the company beat on EPS by $0.04 which was followed by a 30.0% drop in the share price the next day.
Here's a look at Coherus BioSciences's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.31 | -0.52 | -0.57 | -0.84 |
| EPS Actual | -0.27 | -0.38 | -0.75 | -0.60 |
| Revenue Estimate | 83.56M | 50.83M | 47.44M | 51.22M |
| Revenue Actual | 74.57M | 58.72M | 32.44M | 45.35M |
To track all earnings releases for Coherus BioSciences visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CHRS
